These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17613445)
41. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study. Lado E; Vacariza M; Fernández-González C; Gestal-Otero JJ; Figueiras A J Eval Clin Pract; 2008 Jun; 14(3):453-9. PubMed ID: 18373568 [TBL] [Abstract][Full Text] [Related]
42. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)]. Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995 [TBL] [Abstract][Full Text] [Related]
43. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. Blais L; Kettani FZ; Perreault S; Leroux JC; Forget A; Kergoat MJ J Am Geriatr Soc; 2009 Feb; 57(2):366-8. PubMed ID: 19207161 [No Abstract] [Full Text] [Related]
44. Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK. Noble JM BMJ; 2001 Nov; 323(7321):1128. PubMed ID: 11725756 [No Abstract] [Full Text] [Related]
45. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486 [TBL] [Abstract][Full Text] [Related]
46. Determinants of physicians' prescribing behaviour of methylphenidate for cognitive enhancement. Ponnet K; Wouters E; Van Hal G; Heirman W; Walrave M Psychol Health Med; 2014; 19(3):286-95. PubMed ID: 23713799 [TBL] [Abstract][Full Text] [Related]
47. Nationwide use of medicines for Alzheimer's disease by community-dwelling persons in Finland. Alander J; Lönnroos E; Hartikainen S; Klaukka T J Am Geriatr Soc; 2006 Mar; 54(3):557-8. PubMed ID: 16551340 [No Abstract] [Full Text] [Related]
48. Reasons for prescribing cognition enhancers in primary care. Results of a representative survey in Lower Saxony, Germany. Stoppe G; Sandholzer H; Staedt J; Winter S; Kiefer J; Rüther E Int J Clin Pharmacol Ther; 1995 Sep; 33(9):486-90. PubMed ID: 8520805 [TBL] [Abstract][Full Text] [Related]
49. Current status: Alzheimer's Disease. Ghosh R Kathmandu Univ Med J (KUMJ); 2003; 1(3):205-11. PubMed ID: 16388232 [No Abstract] [Full Text] [Related]
50. Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice. Malone DM; Lindesay J Age Ageing; 2007 May; 36(3):331-3. PubMed ID: 17350975 [No Abstract] [Full Text] [Related]
51. FPIN's clinical inquiries. Monitoring therapy for patients with Alzheimer's disease. Raetz J; v d Luft E Am Fam Physician; 2007 Jun; 75(11):1703-4. PubMed ID: 17575663 [No Abstract] [Full Text] [Related]
52. Alzheimer's disease--time to act is now. de Silva HA Ceylon Med J; 2005 Mar; 50(1):1-4. PubMed ID: 15881555 [No Abstract] [Full Text] [Related]
53. Drug therapy in Alzheimer's disease. Meyer MA N Engl J Med; 2004 Oct; 351(18):1911-3; author reply 1911-3. PubMed ID: 15515223 [No Abstract] [Full Text] [Related]
54. Cholinesterase inhibitors for Alzheimer's disease. Hitzeman N Am Fam Physician; 2006 Sep; 74(5):747-9. PubMed ID: 16970018 [No Abstract] [Full Text] [Related]
55. Diffusion of innovations: treatment of Alzheimer's disease in Germany. Ruof J; Mittendorf T; Pirk O; von der Schulenburg JM Health Policy; 2002 Apr; 60(1):59-66. PubMed ID: 11879945 [TBL] [Abstract][Full Text] [Related]
56. Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors. Jones PM; Soderman RM Anaesthesia; 2007 Feb; 62(2):201. PubMed ID: 17223834 [No Abstract] [Full Text] [Related]
57. Female specialists were more likely to respond to a postal questionnaire about drug treatments for Alzheimer disease. Oremus M; Wolfson C J Clin Epidemiol; 2004 Jun; 57(6):620-3. PubMed ID: 15246130 [TBL] [Abstract][Full Text] [Related]